Interestingly, it has been proposed that such interventions could be unfavorable in treating COVID-19, in part due to the Th1/Th17 cytokines involved in hyperinflammation, where IL-13/IL-4 inhibition may further bias in immune activity [55]. This evidence concerns the gene IL13 and COVID-19.